Company intelligence / Profile preview

Orion Genomics

St. Louis, Missouri, United Statesoriongenomics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Orion Genomics has developed proprietary technologies such as MethylScreen for DNA methylation profiling, which have been licensed to major companies like Qiagen. Their CLIA-certified lab supports the translation of research assays into regulated clinical tests. They also commercialize agricultural genomics solutions through their subsidiary. Clinical results per se are not published as they primarily offer services rather than therapeutics.

Therapeutic areas: OncologyOther
Modalities: Molecular diagnosticsGenetic testingBiomarker discoveryEpigenetics-based assaysSequencing-based technologies
Industry: Molecular Diagnostics

Partnerships

Qiagen (licensee of MethylScreen technology)Malaysian Palm Oil Board

Beyond the preview

Go deeper on Orion Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orion Genomics.

Explore the full profile